tinurilimab (BAY1834942) / Bayer, German Cancer Research Center - LARVOL DELTA

A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors. (PubMed, Target Oncol) - P1 | "Following study termination, the clinical development program for tinurilimab was discontinued permanently."

Journal • P1 data • Acute Kidney Injury • Fatigue • Febrile Neutropenia • Hematological Disorders • Metabolic Disorders • Nephrology • Neutropenia • Oncology • Renal Disease • Solid Tumor • CEACAM5 • CEACAM6

A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I-Labeled Tinurilimab. (PubMed, Adv Sci (Weinh)) - "These results proves that 89Zr/131I-labeled tinurilimab facilitates the differential capacity of malignant pulmonary nodules and radioimmunotherapy of LUAD in preclinical models. Further clinical evaluation and translation of this CEACAM6-targeted theranostics may be significant help in diagnosis and treatment of LUAD."

IO biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CEACAM6

Increased T cell- activation resulting from the combination of the anti-CEACAM6 function-blocking antibody BAY 1834942 with checkpoint inhibitors targeting either PD-1/PD-L1 or TIM-3 (AACR 2019) - P1; "The data shown here provide a rationale for examining its combination potential with immune checkpoint inhibitors targeting either PD-1, PD-L1 or TIM-3. BAY 1834942 is currently under investigation in Ph1 clinical trials (NCT03596372)."

Checkpoint inhibition • IO biomarker • Late-breaking abstract • PD(L)-1 Biomarker • Gastrointestinal Cancer • Non Small Cell Lung Cancer • Oncology

T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction. (PubMed, Oncoimmunology) - "In summary, CEACAM6 blockade by BAY 1834942 reactivates the antitumor response of T cells. This warrants clinical evaluation."

IO biomarker • Journal • Colorectal Cancer • Gastrointestinal Cancer • Immune Modulation • Inflammation • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CEACAM1 • CEACAM5 • CEACAM6

Study of BAY1834942 in Patients With Solid Tumors (clinicaltrials.gov) - P1; N=30; Completed; Sponsor: Bayer; Active, not recruiting ➔ Completed

Trial completion • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CEACAM5 • CEACAM6 • IL2

Study of BAY1834942 in Patients With Solid Tumors (clinicaltrials.gov) - P1; N=30; Active, not recruiting; Sponsor: Bayer; Recruiting ➔ Active, not recruiting; N=156 ➔ 30; Trial completion date: Dec 2021 ➔ Nov 2020; Trial primary completion date: Jun 2021 ➔ Oct 2020

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Biliary Cancer • Bladder Cancer • Breast Cancer • Cervical Cancer • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Thoracic Cancer

Study of BAY1834942 in Patients With Solid Tumors (clinicaltrials.gov) - P1; N=156; Recruiting; Sponsor: Bayer; N=296 ➔ 156

Clinical • Enrollment change